S-40503
S-40503 is a tissue-selective androgen receptor (AR) agonist with a Ki of 14.9 nM for rat AR. S-40503 binds to AR with high specificity, exerts full agonistic effects in bone and muscle, acts as a partial agonist in the prostate, and preferentially targets anabolic tissues rather than androgen-dependent tissues. S-40503 can be used in the research of osteoporosis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 404920-28-1
- 分子式: C15H23N3O3
- 分子量:293.36
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
|
Rat AR 14.9 nM (Ki) |
体外実験
S-40503 is a selective, high-affinity androgen receptor binder with minimal cross-reactivity to other nuclear receptors, exhibiting an AR Ki of 14.9 nM[1].
S-40503 binds to androgen receptor with a relative binding affinity of 0.3% compared to DHT[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
S-40503 (30 mg/kg; s.c.; daily; 4 weeks) increases levator ani weight without enlarging the prostate in normal male rats, confirming diminished virilizing activity under physiological androgen conditions[1].
S-40503 (30 mg/kg; s.c.; daily; 8 weeks) stimulates periosteal bone formation to increase femoral cortical bone mass and biomechanical strength in ovariectomized rats, with no effect on cancellous bone[1].
S-40503 (30 mg/kg; s.c.; daily; 4 weeks) directly increases tibial cortical bone mass without affecting hindlimb muscle weight in immobilized orchiectomized rats, while maintaining muscle anabolic activity and reduced virilizing effects[1].
S-40503 (1-30 mg/kg; s.c.; daily; 4 weeks) acts as a tissue-selective androgen receptor agonist in castrated rats, showing similar anabolic activity in muscle and bone to DHT at the highest tested dose but with less stimulatory effect on prostate growth[2].
S-40503 (30 mg/kg; s.c.; daily; 4 weeks) exhibits tissue selectivity in intact male rats, stimulating anabolic muscle growth without affecting prostate tissue weight at the tested dose[2].
S-40503 (s.c.; daily) acts as an anabolic agent to restore bone density, formation, and strength in ovariectomized rats with established osteoporosis[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (male, 11-week-old, 320 to 340 g, bilateral orchiectomy-induced hypogonadism)[1]
-
Dosage:1 mg/kg; 3 mg/kg; 10 mg/kg; 30 mg/kg
-
Administration:s.c.; daily; 4 weeks
-
Result:Increased prostate weight dose-dependently starting at 10 mg/kg.
Reached ~75% of sham levels and plateaued at 30 mg/kg.
Increased levator ani weight significantly at 30 mg/kg, exceeding sham levels.
Increased femoral BMD significantly at 30 mg/kg, exceeding sham levels.
-
Animal Model:Sprague-Dawley (male, 11-week-old, 320 to 340 g)[1]
-
Dosage:30 mg/kg
-
Administration:s.c.; daily; 4 weeks
-
Result:Left prostate weight unchanged relative to vehicle-treated normal rats.
Increased levator ani weight significantly relative to vehicle-treated normal rats.
-
Animal Model:Sprague-Dawley (female, 11-week-old, 200 to 230 g, bilateral ovariectomy-induced postmenopausal bone loss)[1]
-
Dosage:30 mg/kg
-
Administration:s.c.; daily; 8 weeks
-
Result:Increased femoral cortical bone BMD significantly relative to vehicle-treated ovariectomized rats.
Elevated periosteal mineral apposition rate (MAR) markedly relative to vehicle-treated ovariectomized rats.
Increased maximum load and breaking energy of femoral cortical bone significantly relative to vehicle-treated ovariectomized rats, with stiffness showing a non-significant upward trend.
Left femoral cancellous bone BMD unchanged relative to vehicle-treated ovariectomized rats.
-
Animal Model:Sprague-Dawley (male, 11-week-old, 320 to 340 g, bilateral orchiectomy combined with right hindlimb sciatic neurectomy/immobilization)[1]
-
Dosage:30 mg/kg
-
Administration:s.c.; daily; 4 weeks
-
Result:Left gastrocnemius muscle weight unchanged relative to vehicle-treated orchiectomized/neurectomized rats.
Kept prostate weight similar to sham and neurectomy-only rats.
Increased levator ani weight significantly relative to vehicle-treated orchiectomized/neurectomized rats.
Increased tibial cortical bone BMD significantly relative to vehicle-treated orchiectomized/neurectomized rats.
Left tibial cancellous bone BMD unchanged relative to vehicle-treated orchiectomized/neurectomized rats.
-
Animal Model:Male rats (strain not specified)[2]
-
Dosage:1 mg/kg; 10 mg/kg; 30 mg/kg
-
Administration:s.c.; daily; 4 weeks
-
Result:Increased prostate and levator ani muscle weights significantly at 10 and 30 mg/kg/day.
Increased femoral BMD statistically significantly only at 30 mg/kg/day.
Restored prostate weight to ~80% of intact control levels at 30 mg/kg/day.
Restored levator ani muscle weight to ~115% of intact control levels at 30 mg/kg/day.
Increased femoral BMD to a level similar to DHT at 10 mg/kg/day at 30 mg/kg/day.
-
Animal Model:Male rats (strain not specified)[2]
-
Dosage:30 mg/kg
-
Administration:s.c.; daily; 4 weeks
-
Result:Increased levator ani muscle weight by 30% at 30 mg/kg/day.
Did not significantly change prostate weight at 30 mg/kg/day.
化学情報
-
CAS 番号 404920-28-1
-
分子量 293.36
-
分子式 C15H23N3O3
-
SMILES
CC(CO)(C)C1CC(N(C)C)C2=CC([N+]([O-])=O)=CC=C2N1
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (286 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
S-40503 関連分類
HY-103578 関連分類
Powered by Bioz